Participant flow16

How many started, completed or left each group, period by period.

1 to 16 of 16

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo+52 Week Taper	28
Overall Study	STARTED	Placebo+26 Week Taper	14
Overall Study	STARTED	Sarilumab 150mg q2w+26 Week Taper	14
Overall Study	STARTED	Sarilumab 200mg q2w+26 Week Taper	27
Overall Study	Week 52 Analysis Set Population	Placebo+52 Week Taper	10
Overall Study	Week 52 Analysis Set Population	Placebo+26 Week Taper	6
Overall Study	Week 52 Analysis Set Population	Sarilumab 150mg q2w+26 Week Taper	7
Overall Study	Week 52 Analysis Set Population	Sarilumab 200mg q2w+26 Week Taper	13
Overall Study	COMPLETED	Placebo+52 Week Taper	9
Overall Study	COMPLETED	Placebo+26 Week Taper	6
Overall Study	COMPLETED	Sarilumab 150mg q2w+26 Week Taper	6
Overall Study	COMPLETED	Sarilumab 200mg q2w+26 Week Taper	8
Overall Study	NOT COMPLETED	Placebo+52 Week Taper	19
Overall Study	NOT COMPLETED	Placebo+26 Week Taper	8
Overall Study	NOT COMPLETED	Sarilumab 150mg q2w+26 Week Taper	8
Overall Study	NOT COMPLETED	Sarilumab 200mg q2w+26 Week Taper	19

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03600805/flow